Articles

CD16+NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice

Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada;Institute of Medical Science, University of Toronto, Ontario, Canada
Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Quebec, Canada
Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada;Institute of Medical Science, University of Toronto, Ontario, Canada
Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Department of Medical Imaging, University of Toronto, Ontario, Canada;Department of Pharmaceutical Sciences, University of Toronto, Ontario, Canada;Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada
Department of Medical Biophysics, University of Toronto, Ontario, Canada;Department of Medicine, University of Toronto, Ontario, Canada
Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada;Institute of Medical Science, University of Toronto, Ontario, Canada;Department of Medicine, University of Toronto, Ontario, Canada;Institute of Biomaterials and Biomedical Engineering, University of Toronto, Canada;Krembil Research Institute, University Health Network, Toronto, Ontario, Canada
Vol. 103 No. 10 (2018): October, 2018 https://doi.org/10.3324/haematol.2017.187385